Pulmonary Fibrosis Foundation Reveals Top Research Grant Winners for 2015

Pulmonary Fibrosis Foundation Reveals Top Research Grant Winners for 2015

One of the country’s leading organizations dedicated to finding a cure for pulmonary fibrosis (PF), the Pulmonary Fibrosis Foundation (PFF), recently revealed the recipients of this year’s Established Investigator and Junior Investigator Awards. These prestigious research grants are directly supported by the Foundation’s Research Fund to Cure Pulmonary Fibrosis, and given only to…

In IPF Study, Fibroblasts Seen as More Aggressive with USP13 Loss

In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13,…

ProMetic’s PBI-4050 Receives Orphan Drug Designation by the European Commission for Idiopathic Pulmonary Fibrosis Treatment

ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…

ProMetic and FDA Close Successful Pre-IND Meeting for PBI-4050 for Idiopathic Pulmonary Fibrosis

ProMetic Life Sciences, Inc., a biopharmaceutical corporation active in the development of novel therapeutic products targeting unmet medical needs in several fields, including fibrosis, is pleased to announce it recently concluded a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational anti-fibrotic…

Phase III Trials Reveal That IPF Patients Treated Continually with ESBRIET for Long-term Have Reduced Risk of Death

Results from phase III trials with Esbriet® (pirfenidone), a drug developed by Roche, were recently presented at the European Respiratory Society (ERS) congress held in Amsterdam from September 26-30, 2015. The results revealed that Esbriet® is beneficial for long-term treatment of idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by progressive…

New Insights into Exposure to Talc and Risk for Pulmonary Disease Talcosis

A team of researchers from The Netherlands recently discovered that talc (magnesium silicate), often used in the food industry, is a danger to health and exposure to it should be closely monitored. The study findings were recently presented by Dr. Jos Rooijackers, a pulmonologist from the Netherlands Expertise Centre for…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums